Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial
A. Lavolé, Julien Mazières, S. Schneider, Solenn Brosseau, L. Kiakouama, Laurent Greillier, Amélie Guihot, Baptiste Abbar, Marine Baron, Alain Makinson, Alexandra Langlais, Franck Morin, Jean‐Philippe Spano, J. Cadranel
Topics & Concepts
MedicineCommon Terminology Criteria for Adverse EventsNivolumabTolerabilityInternal medicineAdverse effectLung cancerResponse Evaluation Criteria in Solid TumorsProgressive diseaseClinical endpointClinical trialCancerOncologySurgeryChemotherapyImmunotherapyCancer Immunotherapy and BiomarkersViral-associated cancers and disordersLung Cancer Treatments and Mutations